bullish
SD Biosensor (137310 KS): Aggressively Investing Windfall Gain From COVID; Adding New Growth Engines
219 Views16 Oct 2022 17:45
SUMMARY
- In July 2022, SD Biosensor (137310 KS) in partnership with SJL Partners signed a definitive merger agreement to acquire Meridian Bioscience (VIVO US) for approximately KRW800 billion (~$1.5 billion).
- The acquisition will strengthen SD Biosensos’s IVD platform to navigate the decline in COVID-19 testing demand and accelerate its U.S. market entry.
- In September 2021, SD Biosensor acquired ~22% stake in UXN, which aims to launch mini continuous blood glucose meter in domestic market in 2024.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Bionote IPO - Delayed Timeline & Updated Valuation Analysis14 Nov 2022
- BioNote IPO Valuation Analysis18 Oct 2022
- BioNote IPO Preview16 Oct 2022
- SD Biosensor (137310 KS): Aggressively Investing Windfall Gain From COVID; Adding New Growth Engines16 Oct 2022
x